The European Medicine Agency (EMA) encouraged collaboration between EU researchers on high-quality, multi-center observational studies of COVID-19 treatments and vaccines.
High-quality observational research of real world data collected during the pandemic can be an important complement to the results of randomized clinical trials in providing evidence on the safety and effectiveness of vaccines and treatments for COVID-19.
When planning observational studies, researchers should adhere to existing guidelines on the appropriate design and conduct of pharmacoepidemiological studies in order to generate reliable and reproduceable evidence.
A new COVID-19 response group, set up by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), is in place to simplify this collaboration.
For more details, please the official communication from EMA.
Meditrial can help – Contact us for immediate support
Meditrial has developed rapid workflows to conduct risk assessment, implement rescue plans and execute solutions for ongoing clinical trials:
- Identify patients requiring follow-up
- Conduct investigator and study nurse calls for training to address the situation
- Obtain authorizations for decentralized data collection
- Support to patients for alternative access to needed care
- Prepare procedures and worksheets for remote collection of patient clinical data
- Monitor work instructions and trainings for site support and remote monitoring
- EDC and ePRO solutions to enable study continuity
- Privacy protection measures
Contact Meditrial for immediate assistance in Europe or the US.
WOW just what I was searching for.